Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial (Ophthalmology. 2021;128:576-586)
- PMID: 33551286
- DOI: 10.1016/j.ophtha.2020.12.030
Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial (Ophthalmology. 2021;128:576-586)
Comment in
-
Reply.Ophthalmology. 2021 May;128(5):e26-e27. doi: 10.1016/j.ophtha.2020.12.031. Epub 2021 Feb 5. Ophthalmology. 2021. PMID: 33551285 No abstract available.
Comment on
-
C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.Ophthalmology. 2021 Apr;128(4):576-586. doi: 10.1016/j.ophtha.2020.08.027. Epub 2020 Sep 1. Ophthalmology. 2021. PMID: 32882310 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
